TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Option Overview for Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer
Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Treatment options for patients with all stages of ovarian epithelial cancer, fallopian tube cancer (FTC), and primary peritoneal cancer (PPC) have consisted of surgery followed by platinum-based chemotherapy.
Early stage refers to stages I and II. However, because of high recurrence rates for stage II patients in early-stage disease trials, patients with stage II cancers have been included with patients who have more advanced-stage cancer in Gynecologic Oncology Group clinical trials since 2009. Going forward, stage I will remain a separate category for treatment considerations, but high-grade serous stage II cancers are likely to be included with more advanced stages.
Numerous clinical trials are in progress to refine existing therapies and test the value of different approaches to postoperative drug and radiation therapy. Patients with any stage of ovarian cancer are appropriate candidates for clinical trials.[1,2] Information about ongoing clinical trials is available from the NCI website.
Source links and citations
The treatment options for ovarian epithelial cancer, FTC, and PPC are presented in Table 6.
Source links and citations
| Stage | Treatment Options |
|---|---|
| FTC = fallopian tube cancer; HIPEC = hyperthermic intraperitoneal chemotherapy; OS = overall survival; PARP = poly (ADP-ribose) polymerase; PPC = primary peritoneal cancer. | |
| Low-grade serous carcinoma | Surgery with or without chemotherapy |
| Secondary cytoreductive surgery | |
| Targeted therapies | |
| Hormone therapy alone or combined with chemotherapy (under clinical evaluation) | |
| Early-stage ovarian epithelial cancer, FTC, and PPC | Surgery with or without chemotherapy |
| Advanced-stage ovarian epithelial cancer, FTC, and PPC | Surgery followed by platinum-based chemotherapy |
| Surgery before or after platinum-based chemotherapy and/or additional consolidation therapy | |
| Surgery before or after platinum-based chemotherapy and the addition of bevacizumab to induction therapy and/or consolidation therapy | |
| Surgery after platinum-based chemotherapy and the addition of HIPEC | |
| Surgery before or after platinum-based chemotherapy and the addition of PARP inhibitors to induction therapy and/or consolidation therapy | |
| Chemotherapy for patients who cannot have surgery (although the impact on OS has not been proven) | |
| Recurrent ovarian epithelial cancer, FTC, and PPC | Platinum-containing chemotherapy regimens |
| Bevacizumab, other targeted drugs, and PARP inhibitors with or without chemotherapy | |
| Chemotherapy | |
| Chemotherapy and/or bevacizumab | |
| Immune checkpoint inhibitors | |
| Antibody-drug conjugates | |
Source links and citations
- Surgery with or without chemotherapy
- Secondary cytoreductive surgery
- Targeted therapies
- Surgery with or without chemotherapy
- Surgery followed by platinum-based chemotherapy
- Surgery before or after platinum-based chemotherapy and/or additional consolidation therapy
- Surgery before or after platinum-based chemotherapy and the addition of bevacizumab to induction therapy and/or consolidation therapy
- Surgery after platinum-based chemotherapy and the addition of HIPEC
- Surgery before or after platinum-based chemotherapy and the addition of PARP inhibitors to induction therapy and/or consolidation therapy
- Platinum-containing chemotherapy regimens
- Bevacizumab, other targeted drugs, and PARP inhibitors with or without chemotherapy
- Chemotherapy
- Chemotherapy and/or bevacizumab
- Immune checkpoint inhibitors
- Antibody-drug conjugates
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice